DXCM vs KNSA: which is the better buy in 2026?
On Alexandria's Compass, DexCom Inc. has the edge with a 91/100 score versus 90/100 for KNSA. Here is how they stack up, factor by factor.
DexCom Inc.
NASDAQ:DXCM
Stelo is building a second growth engine in a $60B+ population Dexcom has never monetized, and the stock is trading near trough valuation.
Full DXCM analysisKiniksa Pharmaceuticals International, plc
NASDAQ:KNSA
A one-drug company quietly becoming a two-drug franchise, with the second drug potentially bigger than the first.
Full KNSA analysisFactor by factor
Get head-to-heads like this, free
Join the Alexandria e-letter for Compass verdicts, earnings intelligence, and the contrarian calls the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is DXCM or KNSA the better buy in 2026?
By Compass Score, DexCom Inc. (NASDAQ:DXCM) edges it at 91/100 versus 90/100 for KNSA. Both scores update weekly and reflect a contrarian, forward-looking read, not a recommendation.
How does Alexandria compare DXCM and KNSA?
Each company is scored 1-100 on eight factors: revenue growth, profitability, valuation, momentum, theme purity, moat, catalysts, and market position. The Compass Score is the composite, and the comparison below shows where each name wins factor by factor.
Compass Scores are proprietary editorial research from publicly available data, not investment advice or a recommendation regarding any security. Rankings update weekly.